In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival

Alexandra Shingina,Al Moutaz Hashim,Mazhar Haque,Michael Suen,Eric M. Yoshida,Sharlene Gill,Fergal Donnellan,Alan Weiss

In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival

2013

Alexandra Shingina
Al Moutaz Hashim
Mazhar Haque
Michael Suen
Eric M. Yoshida
Sharlene Gill
Fergal Donnellan
Alan Weiss

BACKGROUND: Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). British Columbia (BC) was the first province in Canada to provide drug coverage for sorafenib.

Keywords:

Diabetes mellitus
General surgery
Oncology
Drug
Internal medicine
Hepatocellular carcinoma
Medicine
Pharmacology
Retrospective cohort study
Sorafenib
Survival rate
Cancer
Surgery
Alcoholic liver disease
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations